Intravitreal injection of VEGF blockers is a first-line therapy for several ocular disorders including AMD; however, the anti-VEGF strategy is not necessarily effective for all patients.47, 48 Despite the successful results of numerous prospective clinical trials, 10% to 30% of patients have been shown to be non-responders for anti-VEGF drugs. This evidence concerns the gene VEGFA and age-related macular degeneration.